Michael Thomas

Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis

M. Kriegsmann, F. Herth, C. Heussel, 2022, BMC Pulmonary Medicine.

Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial

C. Heussel, M. Kreuter, J. Krisam, 2022, BMC Cancer.

Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors

D. Kazdal, H. Sültmann, P. Schnitzler, 2022, Frontiers in Oncology.

Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression

R. Horos, K. Tikk, B. Steinkraus, 2022, JTO clinical and research reports.

Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report

M. Kriegsmann, D. Kazdal, C. Heussel, 2022, Cold Spring Harbor molecular case studies.

Dynamic contrast enhanced MRI of pulmonary adenocarcinomas for early risk stratification: higher contrast uptake associated with response and better prognosis

H. Kauczor, C. Heussel, J. Dinkel, 2022, BMC Medical Imaging.

Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients

H. Sültmann, T. Muley, M. Reck, 2022, Clinical Epigenetics.